Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Charles Dadswell

Premium

Illumina has named Charles Dadswell senior vice president and general counsel, replacing Christian Cabou, who has retired. Dadswell will be responsible for all legal and intellectual property matters and will also serve as secretary to Illumina's board of directors. He joins Illumina from BioMérieux, where he served as vice president and general counsel for North and Latin America and corporate director of global intellectual property. Previously, he was general counsel at BioDelivery Sciences International, a specialty pharmaceutical company. He holds an LLM in patent law and trade regulation from George Washington University Law School, a JD from the Thomas M. Cooley Law School, and a BS from Ferris State University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.